GC Green Cross launches Rosetelpine, a 4-drug combination for hypertension and hyperlipidemia

GC Green Cross's four-drug combination for hypertension and hyperlipidemia, 'Rozetelpine' (Photo by GC Green Cross)

[Asia Economy Reporter Chunhee Lee] GC Green Cross announced on the 21st that it has launched 'Rozetelpine,' a four-drug combination therapy for hypertension and hyperlipidemia.

Rozetelpine is a prescription drug that contains antihypertensive agents telmisartan and amlodipine, and hyperlipidemia treatment agents rosuvastatin and ezetimibe in a single pill.

Following the three-drug combination 'Rozetel' (rosuvastatin, ezetimibe, telmisartan) launched in May, GC Green Cross plans to provide effective treatment options for patients with hypertension and hyperlipidemia with this new four-drug combination Rozetelpine, which additionally contains amlodipine.

The company explained that the efficacy of Rozetelpine was confirmed in a Phase 3 clinical trial conducted in 2020 involving about 130 domestic patients with hypertension and hyperlipidemia. The clinical results demonstrated that Rozetelpine was effective in controlling mean systolic blood pressure (msSBP) and low-density lipoprotein cholesterol (LDL-C) compared to the control group.

A GC Green Cross official said, "More than 50% of hypertension patients also have hyperlipidemia, which causes inconvenience due to the need to take multiple individual medications. We hope that taking four components in one pill will help improve patients' quality of life."

In addition, GC Green Cross has a lineup of chronic disease treatments including hyperlipidemia drugs 'Dabiduo' and 'Aziduo,' antihypertensive drugs 'Neocande' and 'Candedipine,' and a two-drug combination for hypertension and hyperlipidemia called 'Rotacan.'

This content was produced with the assistance of AI translation services.